NCT00054691View on ClinicalTrials.gov

ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Skin Cancer
Interventions
DRUG

Iressa

250 mg by mouth daily

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER